Zydus Cadila

Zydus Life has clarified that there has been no official communication regarding permission for the two-dose regimen of the needle-less ZyCoV-D vaccine. ZyCov-D, an indigenous DNA-plasmid-based vaccine against Sars-Cov-2, was given emergency use authorisation for restricted use last year by the Central Drugs Standard Control Organisation (CDSCO). The three-dose vaccine was found to be over 66% effective in the third phase clinical trial.

The order of 1 crore Zydus Cadila’s three-dose Covid vaccines has been placed by the Indian government at 265 rupees per dose. Reportedly, the world's first DNA-based vaccine is given at day zero, day 28th and then on the 56th day. The vaccine will be administered with a needle-free applicator, called ''PharmaJet''. ''The pricing has been decided in consultation with the Government of India," said the Gujarat-based firm.

After conducting the largest clinical trials in more than 50 centers, Zydus Cadila's three-dose Covid vaccine "ZyCoV-D" may soon get the government's approval for emergency use in India. The Gujarat-based pharmaceutical company has been listed for emergency use authorization (EAU) with the Indian Drug regulator and is likely to produce around 10-12 crore doses in a year. Reportedly, the ZyCoV-D vaccination will be administered to the adults… read-more

Pharmaceutical giant Zydus Cadila has announced that a dose of its COVID-19 drug 'Virafin' will cost Rs 11,995. The company has claimed that Virafin will lessen the need for oxygen in COVID-19 patients. The drug was earlier approved by the Drug Controller General of India on April 23 for treatment of mild COVID-19 cases.  Meanwhile, Zydus is also in the process to launch its three-dose COVID-19 vaccine Zy-CoV-D.